AMPLIA THERAPEUTICS LIMITED (ATX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ATX

ATX - AMPLIA THERAPEUTICS LIMITED

FNArena Sector : NONE
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.19

07 Aug
2025

0.010

OPEN

$0.18

5.56%

HIGH

$0.19

9,554,622

LOW

$0.17

TARGET
$0.42 121.1% upside
FNARENA'S MARKET CONSENSUS FORECASTS
ATX: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 2.1 - 1.8 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-2.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx5.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-6.9 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-40.51 %
Return on Invested Capital xxxxxxxxxxxxxxx-40.50 %
Return on Assets xxxxxxxxxxxxxxx-34.79 %
Return on Equity xxxxxxxxxxxxxxx-40.51 %
Return on Total Capital xxxxxxxxxxxxxxx-62.18 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-6.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx11 M
Price To Book Value xxxxxxxxxxxxxxx1.29

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx8 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

08/08/2025

1

Speculative Buy

$0.42

121.05%

Amplia Therapeutics announced top-line data from the single-arm Phase 2 Accent trial for narmafotinib plus chemotherapy in metastatic pancreatic cancer patients. 

Bell Potter views the new data, which showed median progression-free survival duration at 7.6 months, as a positive outcome, as it was above the threshold of 7.5 months, which represents a two-month extension.

The next key points include the FDA feedback on the potential approval pathway in 4Q2025, with further Accent interim data in that quarter, and the overall (mature data) for survival from the trial in 1Q2026.

No change in Speculative Buy rating, 42c target price or EPS estimates.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.80 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -2.10 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

ATX STOCK CHART

FNArena News on ATX

1
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps